No Data
No Data
Shandong Xinhua Pharmaceutical Company Limited Goes Ex Dividend Monday
Shandong Xinhua Pharmaceutical (000756.SZ): research and development investment in 2023 reached 0.406 billion yuan.
Shandong Xinhua Pharmaceutical (000756.SZ) stated on the investor interaction platform on July 15th that the company has continued to increase its research and development investment in recent years, with a research and development investment of 0.406 billion yuan in 2023 and over 100 innovative drugs and generics in the R&D pipeline.
Changjiang Securities: The vitamins D3 market is good and the business outlook is positive.
Vitamin D3 is a minor variety in the vitamins industry, mainly used in the field of fodder. With the gradual digestion of overseas market inventory and the steady recovery of domestic demand, the product demand side has been catalyzed marginally. As a high-quality industry with highly concentrated supply of raw materials, the leading players have a greater say and prices have greater elasticity.
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
No Data
whqqq : Will more capital flow into the Hong Kong market after the delisting crisis?
HopelessChi whqqq: future is solid red. must be some amazing news crashing the future of HSI/HST
whqqq HopelessChi: What's the bad news?
海纳百川 whqqq: It will take longer for the market to recover; currently, it is still mainly bearish
whqqq 海纳百川: OKAY...Thank you for your answer